Product Description
A first polypeptide that from N-terminal to C-terminal comprises a second light chain variable domain (VL2) binding a second target and a first heavy chain variable domain (VH1) binding a first target, wherein the VL2 is linked to the VH1 via a linker; a second polypeptide that from N-terminal to C-terminal comprises a first light chain variable domain (VL1) binding a first target and a second heavy chain variable domain (VH2) binding a second target, as well as a cysteine-containing hinge domain and a CH2-CH3 domain of IgG, wherein the VL1 is linked to the VH2 via a linker; a third polypeptide that from N-terminal to C-terminal comprises a cysteine-containing hinge domain and a CH2-CH3 domain of IgG. (Sourced from: https://patents.google.com/patent/EP3988575A1/en?q=(cd19)&assignee=chimagen&before=publication:20240814&after=publication:20220101&oq=(cd19)+assignee:(chimagen)+before:publication:20240814+after:publication:20220101)
Mechanisms of Action: CD19 Inhibitor,BCMA Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Trispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chimagen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|